Curated News
By: NewsRamp Editorial Staff
April 30, 2026

HeartBeam to Report Q1 2026 Results, Updates on Arrhythmia Launch

Discuss on Substack Discuss on Telegram View History of this news story on GitHub
Original Source

TLDR

  • HeartBeam's FDA-cleared 3D ECG tech and upcoming earnings call signal a competitive edge in cardiac diagnostics.
  • HeartBeam synthesizes 3D ECG signals into a 12-lead ECG using a cable-free device, enabling portable cardiac monitoring.
  • HeartBeam's technology allows patients to receive cardiac care anywhere, potentially saving lives through early detection.
  • HeartBeam's 3D ECG collects signals from three directions, a first-ever innovation for portable heart monitoring.

Impact - Why it Matters

HeartBeam's innovative 3D ECG technology, which received FDA clearance for arrhythmia assessment and 12-lead synthesis, represents a paradigm shift in cardiac care. By enabling portable, cable-free ECG monitoring outside medical facilities, it promises earlier detection of heart attacks and improved management of arrhythmias, potentially reducing hospital visits and healthcare costs. For investors and patients, this news matters because it signals progress toward commercializing a disruptive technology that could redefine cardiac health management.

Summary

HeartBeam (NASDAQ: BEAT), a medical technology company focused on cardiac care innovation, will host a conference call on May 13, 2026, at 4:30 p.m. Eastern time to discuss first-quarter results ended March 31, 2026, and provide updates on key growth initiatives, including its limited commercial launch for arrhythmia assessment, extended-wear patch development, heart attack detection and AI programs.

HeartBeam is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. The Company holds over 20 issued patents related to technology enablement. The full press release is available at https://ibn.fm/yN939.

This news is distributed by NetworkNewsWire (“NNW”), a specialized communications platform focusing on financial news and content distribution. NNW is part of the Dynamic Brand Portfolio @ IBN, which delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution via IBN, and a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, HeartBeam to Report Q1 2026 Results, Updates on Arrhythmia Launch

blockchain registration record for this content.